MX2009003082A - Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl. - Google Patents
Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl.Info
- Publication number
- MX2009003082A MX2009003082A MX2009003082A MX2009003082A MX2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A
- Authority
- MX
- Mexico
- Prior art keywords
- leukemia
- tyrosine kinase
- abl tyrosine
- cmin
- bcr
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Ecology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona un método para el tratamiento de leucemia positiva para Filadelfia (Ph+), tal como leucemia linfoblástica aguda positiva para el cromosoma Filadelfia (Ph+ ALL) o leucemia mieloide crónica (CML), en una población de pacientes humanos, el cual comprende los pasos de: (a) administrar una cantidad fija previamente determinada de un inhibidor de cinasa de tirosina Bcr-Abl, tal como imatinib, o una sal farmacéuticamente aceptable del mismo, a los pacientes humanos que sufran de una leucemia Ph+, (b) recolectar cuando menos una muestra de sangre de estos pacientes, (c) determinar el nivel en plasma de artesa (Cmin) del inhibidor de cinasa de tirosina Bcr-Abl, o de un metabolito del mismo, así como los índices de respuesta molecular mayor, (d) evaluar un potencial de discriminación de la concentraciones en plasma de artesa para la respuesta molecular mayor, e identificar un umbral de Cmin para la sensibilidad y especifidad óptimas, y (e) ajustar la dosis del inhibidor de la cinasa de tirosina Bcr-Abl, o una sal farmacéuticamente aceptable del mismo, aplicada a los pacientes individuales a partir de la población de pacientes mencionada, y opcionalmente, a pacientes futuros que sufran de una leucemia Ph+ de una manera en que se alcance una Cmin en cada paciente individual igual o mayor que el umbral de Cmin obtenido de acuerdo con el paso (d).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82662206P | 2006-09-22 | 2006-09-22 | |
| US82827806P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/078978 WO2008036792A2 (en) | 2006-09-22 | 2007-09-20 | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003082A true MX2009003082A (es) | 2009-04-01 |
Family
ID=39092883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003082A MX2009003082A (es) | 2006-09-22 | 2007-09-20 | Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20090281113A1 (es) |
| EP (2) | EP2251042A3 (es) |
| JP (1) | JP5735742B2 (es) |
| KR (1) | KR20090065512A (es) |
| AT (1) | ATE495761T1 (es) |
| AU (1) | AU2007299764B2 (es) |
| BR (1) | BRPI0717099A2 (es) |
| CA (1) | CA2662977A1 (es) |
| CL (1) | CL2007002725A1 (es) |
| CY (1) | CY1111356T1 (es) |
| DE (1) | DE602007012122D1 (es) |
| DK (1) | DK2068938T3 (es) |
| HR (1) | HRP20110250T1 (es) |
| IL (1) | IL197296A (es) |
| MA (1) | MA30786B1 (es) |
| MX (1) | MX2009003082A (es) |
| NO (1) | NO20091490L (es) |
| NZ (1) | NZ575113A (es) |
| PL (1) | PL2068938T3 (es) |
| PT (1) | PT2068938E (es) |
| TN (1) | TN2009000094A1 (es) |
| TW (1) | TWI398251B (es) |
| WO (1) | WO2008036792A2 (es) |
| ZA (1) | ZA200901220B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2526537T3 (es) | 2008-01-23 | 2015-01-13 | Novartis Ag | Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa |
| WO2010065433A1 (en) | 2008-12-01 | 2010-06-10 | Novartis Ag | Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate |
| US20110046919A1 (en) | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
| FR2943418A1 (fr) * | 2009-03-17 | 2010-09-24 | Centre Nat Rech Scient | Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications |
| JPWO2015076213A1 (ja) * | 2013-11-22 | 2017-03-16 | 国立研究開発法人国立成育医療研究センター | 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ−ｐｄｇｆｒｂ |
| US9683220B2 (en) * | 2015-07-07 | 2017-06-20 | Codexis, Inc. | P450-BM3 variants with improved activity |
| IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
| CN114994213A (zh) * | 2022-06-28 | 2022-09-02 | 北京赛诺浦生物技术有限公司 | 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| ID30460A (id) | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | Inhibitor-inhibitor protein siklik tirosin kinase |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| AU2003227639A1 (en) * | 2002-04-17 | 2003-10-27 | Novartis Ag | Methods to predict patient responsiveness to tyrosine kinase inhibitors |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
-
2007
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 EP EP10171365A patent/EP2251042A3/en not_active Withdrawn
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 EP EP07842842A patent/EP2068938B1/en active Active
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en not_active Ceased
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
-
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
-
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
-
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000094A1 (en) | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors | |
| Cappuzzo et al. | Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) | |
| EA201190042A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| KR20050037510A (ko) | 키나제 억제제를 사용하는 암 치료 방법 | |
| KR102425655B1 (ko) | 수면 개선 방법 | |
| Bonifacio et al. | Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy | |
| WO2010066891A3 (en) | Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients | |
| RU2010101634A (ru) | Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi | |
| RU2020134183A (ru) | Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| BRPI0518795A2 (pt) | mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio | |
| Motegi et al. | Role of endothelin‐1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| Wajid et al. | Early molecular response with imatinib therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size | |
| RU2011122721A (ru) | Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl | |
| US20110224224A1 (en) | Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate | |
| Ozgur-Akdemir et al. | Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue | |
| TW200507828A (en) | Method for treatment of chemotherapy-induced diarrhea | |
| Rodriguez et al. | AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS | |
| CN102526734A (zh) | 治疗年龄相关性听力损失的药物组合物及其应用 | |
| Chen et al. | The Role of Abnormal Expression of Clock Gene DBP Mediated by Gut Microbiota Dysbiosis in Cognitive Dysfunction in ESRD and the Underlying Mechanism: PO2485 | |
| Pianka et al. | GENE-38. IDH1MUT INDUCES N6-METHYLADENOSINE (m6A) RNA HYPERMETHYLATION VIA D-2-HG IN GLIOMA | |
| Radich | The (near) miracle of therapy in chronic myeloid leukaemia. | |
| DeLalio et al. | Circadian Cycle Exaggerates Sympathoexcitatory Responses to Activation of Chemosensitive Renal Sensory Nerves: PO2486 | |
| WO2001045690A3 (en) | Use of bvdu for inhibiting the growth of hyperproliferative cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |